Skip to content
The Bio Report cover art

All episodes

The Bio Report, 641 episodes. Page 6 of 7.

#
Title
501

Reflections on the Progress and Promise of Personalzied Medicines

502

Curing Cancer with Math

503

How Healthcare Consumer Find and Use Price Information

504

Why Infectious Disease Represents a National Security Threat

505

Recent Mumps Outbreaks Raise Question If New Vaccine Is Needed

506

Proposed Legislation Would Weaken Genetic Privacy Protections

507

How Biomarkers Can Alter the View of and Approach to Alzheimer’s Disease

508

The Fight for Personalized Medicine Wages on Many Fronts

509

Big Pharma and the Growth and Outlook for Orphan Drugs

510

What the Recent Patent Ruling Means for the Future of Gene-Editing Technology

511

Weighing What Limits Should Be Put on Gene Editing

512

Enlisting the Immune System in the War on Cancer

513

Why Scientists Must Also Be Advocates

514

Sernova Eyes Range of Disease for Implantable Cell Technology

515

Stratus Wants to Demonstrate Its Telehealth Fluency

516

Regeneron Embraces Genetics as Fundamental to Drug Development

517

Despite FDA Setback, KemPharm Advancing Prodrug Pipeline

518

Using digital technologies to improve diagnosis and treatment of mental health patients

519

Biotech in 2016 and the Year Ahead with TheStreet’s Adam Feuerstein

520

Harnessing Gut Bacteria to Treat Disease

521

A Look at What’s Ahead for Biopharma in 2017

522

AMA Wants Docs to Have Seat at mHealth Table

523

Testing of New HIV Vaccine Carries Hopes of a Breakthrough

524

Centrexion Takes Aim at Pain with Growing Portfolio of Non-Opioid Therapeutics

525

Bringing Women into Biotech Boardrooms

526

Novartis Deal Validates Perlara’s Approach to Rare Disease Drug Discovery

527

Harvesting the Aquatic Microbiome for New Drugs

528

How TwoXAR Is Using Big Data to Accelerate Drug Discovery

529

Developer of innovative catheter for cancer drugs turns to crowdfunding

530

Harnessing Real World Samples and Data to Speed Biomedical Research

531

A Rich Pipeline Expected to Drive Industry’s Growth

532

Harnessing Biology to Transform the Economy

533

How a Predictive Diagnostic Can Reduce Preterm Births

534

Building Better Drugs for Psychiatric Disorders by Targeting the Causes

535

The Role of PBMs in the Controversy over Drug Pricing

536

Why a Rare Genetic Disease May Shed Light on Normal Aging

537

Battling Zika and Other Diseases Like It

538

Chronicling a Trailblazer of the Genomics Age

539

Great Progress, but Concerns Persist About Cancer Care in America

540

Improving Healthcare by Addressing the Most Challenging Patients

541

The Case for Chasing Unpopular Indications

542

Improving Drug Development through Better Use of Biomarkers

543

Measuring the Value of Incubators and Accelerators

544

Enlisting New and Old Tools to Combat Antibiotic Resistance

545

Advancing Cancer Care with New Diagnostic Tools

546

A Biotech Reinvents Itself and How to Price Drugs

547

Using Technology to Modernize Preclinical Development

548

Can the Biotech Industry Stay on Track through Innovative Pricing

549

Wall Street Turns Its Eyes to ASCO

550

Understanding the Disease It Never Was on House

551

Why the State of Innovation Is Encouraging

552

Can Market Forces Fix Drug Pricing

553

Digital Health Device Seeks to Push Beyond Cannabis to Test Food, Air, and Water

554

Why the Cancer Moonshot Offers a Chance to Rethink Funding Priorities

555

Medtronic Advances Toward an Artificial Pancreas

556

Using Real-Time Data to Detect HIV Outbreaks

557

Why Pharma Needs to Forge New Drug Pricing Models

558

Gensight Targets Gene Therapy on Diseases that Blind

559

A Vial Problem: How We Waste $3 Billion of Cancer Drugs a Year

560

The Havoc-Wreaking Zombies Lurking in Life Sciences Boardrooms

561

New FDA Chief Faces Challenges

562

Seeking a Best-in-Class Antibody at Bargain Basement Prices

563

Pharma Bro, Price Controls, and the Quest to Balance Innovation with Affordability

564

California’s Stem Cell Agency Plots Its Future

565

ViaCyte Pursues ”Functional Cure” for Type 1 Diabetes

566

Building a Better Pain Pill

567

Project GENIE Hopes to Make Precision Medicine a Reality

568

FDA Wants Industry to Guard Against Cybersecurity Risks of Medical Devices

569

Pharma’s Leadership Vacuum and Its Price to the Industry

570

Permanent R&D Tax Credit a Boost to Life Sciences

571

Biotech in 2015 and the Year Ahead with TheStreet’s Adam Feuerstein

572

Trends Shaping the New Health Economy in 2016

573

Declining R&D Productivity Continues to Plague Big Pharma

574

Searching for Solutions to Rising Specialty Drug Prices

575

Biohackers Seek a Faster, Cheaper Path to Insulin

576

A Scorecard to Improve Drugmakers’ Transparency

577

Forget the Chemistry Set, Mom, I Want a Bioreactor

578

Ensuring Biological Tools Benefit the Environment

579

New SEC Rules Open Crowdfunding to the Masses

580

Harnessing Biology to Address Global Challenges

581

Immunotherapies ETF Lets Biotech Investors Bet on Emerging Sector

582

Biotech Investors Turn Their Eyes to Policy Matters

583

Why the MedTech Industry Should Worry About Future Innovation

584

Rare Disease Drug Developer Shows Speed of Business Model

585

Ensuring Value-Based Care Addresses What Matters to Patients

586

California, Aid-in-Dying, and What We’ve Learned from Oregon

587

FDA Guidance on Names for Biologics and Biosimilars and its Implications

588

Understanding the Cost and Value of Cancer Therapies

589

Jimmy Carter’s Final Wish: Eradicating Guinea Worm

590

The Quest for a Pink Viagra

591

Free Speech Ruling May Force FDA to Rethink Off-Label Marketing

592

Drugmakers Often Late to Report Serious Side Effects

593

When Hospital Cause, Rather than Cure, Deadly Infections

594

Rethinking the Value and Price of Drugs

595

Harnessing Stem Cells to Test Drug Safety

596

CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries

597

Biotech’s Record Performance and Looming Threats

598

What a Decade of Investment Tells Us about the Health of Biotech

599

What Activist Investors Can Teach Biotech Companies

600

ALS Fight Carries Muller from Patient to Biotech CEO